Oral News and Research

RSS

First Edition: March 12, 2012

Today's health policy headlines focus significant attention on key issues, dynamics and even personalities that will be in play when the Supreme Court takes up the health law later this month.

12 Mar 2012

Root cause of dental phobia

Women in their forties are more likely to have dental anxiety than any other age group according to a University of Sydney study into dental anxiety and phobia.

11 Mar 2012

Viewpoints: The fight against IPAB; Chinks in GOP armor on health care law

As part of their broader campaign to repeal health care reform, House Republicans are determined to kill off an independent board that is supposed to help rein in federal spending on Medicare. Their rhetoric is predictably distorted: charging that "15 unelected bureaucrats" should not be able to "ration care." In truth, the independent payment advisory board of nongovernmental experts is specifically precluded from rationing care, and Congress, not the board, has the final say on what cuts should be made.

11 Mar 2012

State highlights: Texas doctors feeling the effects of budget cuts; Iowa advocates seeking better services for disabled

(Dr. Javier Saenz's) troubles reflect a statewide problem for doctors who treat a disproportionately high number of the reported 320,000 low-income Texans who are fully and dually eligible for Medicare, the federal insurer of the elderly, and Medicaid, the joint state-federal health care program for indigent children, the disabled and the very poor.

11 Mar 2012

Even low-dose nanoparticles could have big impact on long-term health

Nanoparticles are everywhere. From cosmetics and clothes, to soda and snacks. But as versatile as they are, nanoparticles also have a downside, say researchers at Binghamton University and Cornell University in a recent paper published in the journal Nature Nanotechnology. These tiny particles, even in low doses, could have a big impact on our long-term health.

9 Mar 2012

New hybrid aspirin shrinks tumors, curbs cancer cell growth

The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.

9 Mar 2012

Unigene fourth quarter net income increases to $4.4 million

Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.

9 Mar 2012

Study investigates knowledge about khat among medical students in Yemen

A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.

8 Mar 2012

Study highlights challenges of adherence in successful deployment of PrEP interventions

"Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) interventions," HIV Medicine Association Executive Director Andrea Weddle writes in this guest post in the Center for Global Health Policy's "Science Speaks" blog.

8 Mar 2012

Zalicus fourth quarter revenue decreases to $8.2 million

Zalicus Inc. today reported financial results for the fourth quarter and year ended December 31, 2011.

8 Mar 2012

CTI fourth quarter net loss decreases to $17.9 million

Cell Therapeutics, Inc. today reported financial results and recent accomplishments for the fourth quarter and year ended December 31, 2011.

7 Mar 2012

Supreme Court swing votes; The Medicaid challenge; And how other rulings might help handicap the action

On the last of three days of arguments on the Affordable Care Act later this month, the U.S. Supreme Court will turn to the sleeper issue that could have the biggest impact on federal power -- Congress' authority under its spending power to require a big expansion of state Medicaid programs.

7 Mar 2012

Merck announces results from AIT Phase III clinical study for ragweed allergy

Merck, known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen.

6 Mar 2012

$Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL$

Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma.

5 Mar 2012

Santarus fourth quarter total revenues increase 65% to $42.6M

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the three and 12 month periods ended December 31, 2011.

5 Mar 2012

Merck announces success of pill against ragweed allergy

Merck & Co. announced Monday that their experimental allergy tablet reduced allergic reactions to ragweed and helped patients use less medication to treat their symptoms.

5 Mar 2012

Pre-registration deadline for European Congress on Osteoporosis & Osteoarthritis

Join the IOF and ESCEO in Bordeaux, France for Europe's premier bone event.

5 Mar 2012

Zalicus completes reformulated Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.

5 Mar 2012

IRIN examines pilot project to increase ORS coverage for treatment of child diarrhea

IRIN examines ColaLife -- a pilot project set to start in Zambia in September 2012 that will ship single-dose anti-diarrhea kits (ADKs) in crates of Coca-Cola bottles in an effort to increase the coverage of oral rehydration salts (ORS) for the treatment of diarrhea in children in the developing world.

5 Mar 2012

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

5 Mar 2012